RecruitingPhase 2NCT06232655

Cladribine Venetoclax in Monocytic AML

Study of Cladribine+Venetoclax After Failure of Venetoclax+Hypomethylating Agent in Monocytic AML

Sponsor

University of Colorado, Denver

Enrollment

20 participants

Start Date

Feb 8, 2024

Study Type

INTERVENTIONAL

Conditions

Acute Myeloid Leukemia

Summary

Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a combination of two drugs — cladribine and venetoclax — for patients with a specific type of acute myeloid leukemia (AML) that has not responded to or has come back after standard treatment with a drug combination called HMA plus venetoclax. **You may be eligible if...** - You are 18 or older - You have AML with a monocytic or monoblastic type, or a specific RAS gene mutation - Your AML came back or did not respond after treatment with a hypomethylating agent (HMA) plus venetoclax - Your kidneys and liver are functioning adequately - You are reasonably active and able to care for yourself **You may NOT be eligible if...** - You have the APL subtype of leukemia - You have severe kidney or liver problems - You are pregnant or not using contraception - You have certain heart conditions or bleeding disorders Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCladribine

A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.

DRUGVenetoclax

A medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).

DRUGAzacitidine

Medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA.. Azacitidine and its deoxy derivative, decitabine were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.

Locations(1)

Universtiy of Colorado Hospital

Aurora, Colorado, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06232655

Related Trials

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649220 locations

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393177 locations

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390346 locations

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT05554406220 locations

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

NCT070191551 location